Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Personalized Medicine
|
May 23, 2018
Can and should value-based pricing be applied to molecular diagnostics?
Martina Garau, Adrian Towse, Louis Garrison, et al.
Journal of Personalized Medicine
|
January 7, 2015
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned
Adrian Towse, Diego Ossa, David Veenstra, et al.
Applied Health Economics and Health Policy
|
April 29, 2024
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study
Theodore Laetsch, Jie Zhang, Hongbo Yang, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 25, 2022
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies
Meng Li, Louis Garrison, Woojung Lee, et al.
Journal of the International AIDS Society
|
August 13, 2019
Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA
Blythe Adamson, Louis Garrison, Ruanne V Barnabas, et al.
Future Oncology (London, England)
|
January 23, 2024
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
William Wong, Stacey Kowal, Tu My To, et al.
Health Affairs (Project Hope)
|
December 8, 2011
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment
Scott D Ramsey, David Veenstra, Sean R Tunis, et al.
Plos One
|
December 26, 2025
Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis
Wadih Mina, Hanadi Nahas, Maria Rita Lteif, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 4, 2019
The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study
Blythe Adamson, Wafaa El-Sadr, Dobromir Dimitrov, et al.
The Patient
|
February 29, 2024
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits
Kevin Marsh, Hannah Collacott, Jim Thomson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Personalized Medicine
|
May 23, 2018
Can and should value-based pricing be applied to molecular diagnostics?
Martina Garau, Adrian Towse, Louis Garrison, et al.
Journal of Personalized Medicine
|
January 7, 2015
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned
Adrian Towse, Diego Ossa, David Veenstra, et al.
Applied Health Economics and Health Policy
|
April 29, 2024
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study
Theodore Laetsch, Jie Zhang, Hongbo Yang, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 25, 2022
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies
Meng Li, Louis Garrison, Woojung Lee, et al.
Journal of the International AIDS Society
|
August 13, 2019
Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA
Blythe Adamson, Louis Garrison, Ruanne V Barnabas, et al.
Future Oncology (London, England)
|
January 23, 2024
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
William Wong, Stacey Kowal, Tu My To, et al.
Health Affairs (Project Hope)
|
December 8, 2011
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment
Scott D Ramsey, David Veenstra, Sean R Tunis, et al.
Plos One
|
December 26, 2025
Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis
Wadih Mina, Hanadi Nahas, Maria Rita Lteif, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 4, 2019
The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study
Blythe Adamson, Wafaa El-Sadr, Dobromir Dimitrov, et al.
The Patient
|
February 29, 2024
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits
Kevin Marsh, Hannah Collacott, Jim Thomson, et al.
Page
of 2